Karyopharm Therapeutics Inc. recently delivered a corporate presentation highlighting their focus on the transformative opportunity in treating myelofibrosis with selinexor (XPOVIO®/NEXPOVIO®). The presentation detailed the growing global demand for selinexor, which is now approved in over 45 countries. The company anticipates a peak annual revenue opportunity of up to $1 billion in myelofibrosis. Karyopharm is conducting the Phase 3 SENTRY trial for selinexor in myelofibrosis, with top-line data expected in late 2025/early 2026. Additionally, the company continues to invest in its pipeline, including in endometrial cancer and multiple myeloma. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.